Kurs & Likviditet
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Informationsteknik |
| Industri | Programvara |
Aiforia Technologies Plc Press Release 26 February 2024 at 2:00 p.m. EET
Aiforia will publish its Financial Statements Bulletin 2023 on 7 March 2024
Aiforia will publish its Financial Statements Bulletin for financial year 2023 on Thursday, 7 March 2024, at around 9.00 a.m. EET. After publication, the financial statements will be available on the company's website at https://investors.aiforia.com/.
Aiforia will host a webcast event at 10:00 a.m. EET on the same day. The event will be chaired by CEO Jukka Tapaninen and will include a review of the company's financial performance and the progress of its strategy during the reporting period.
The event can be followed at https://aiforia.videosync.fi/q4-2023. Participants can ask questions via chat function on the video platform.
A recording of the event and the presentation materials will be published after the event on the company's website https://investors.aiforia.com/.
The event can also be attended on-site at Sanomatalo, Töölönlahdenkatu 2, Helsinki. Please register for the event by Monday, 4 March at 4:00 p.m. EET at the latest by sending an e-mail to ir@aiforia.com.
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc, tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Oy, tel. +358 9 25 380 225
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more at www.aiforia.com